.The InstituteThe Centre for Genomic Regulation (CRG) is an international biomedical research institute of excellence, based in Barcelona, Spain, with more than 400 scientists from 44 countries.
The CRG is composed of an interdisciplinary, motivated and creative scientific team supported by flexible and efficient administration and high-end innovative technologies.In April 2021, the Centre for Genomic Regulation (CRG) received the renewal of the 'HR Excellence in Research' Award from the European Commission.
This is a recognition of the Institute's commitment to developing an HR Strategy for Researchers, designed to align practices and procedures with the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers (Charter and Code).Please check out our Recruitment Policy.The roleWe are seeking a motivated postdoctoral scientist to lead a project in one of these two areas:Analysis and discovery of rare noncoding mutations causing diabetes, using advanced statistical genetics, computational regulatory genomics, and analysis of whole genome sequences in unique patient cohorts.Using computational strategies to develop a high resolution epigenomic technology with translational potential.About the labThe Regulatory Genomics and Diabetes lab aims to uncover genetic mechanisms causing diabetes mellitus and to develop therapeutic avenues.
The group is particularly interested in understanding how genomic information is used to direct cell-specific gene expression and to pinpoint gene regulatory defects underlying human disease.The team brings together diverse expertise, including work with mutant stem cell-derived beta cell organoids, engineered mouse models, single cell epigenomics, large-scale genetic screens, statistical genetics, and the integration of genetic and regulatory data.
This multidisciplinary approach provides unique opportunities for collaborative projects that combine experimental and computational methods.Recent studies from the lab include:A lineage-specific gene transcription and splicing hierarchy that is disrupted in type 2 diabetes.
(In review).Large-scale discovery of molecular targets for precision treatment of HNF1A-deficient diabetes.
(In review).Transcription regulation by long non-coding RNAs and its disease relevance (Nat Rev Mol Cell Biol, 2024).HASTER lncRNA promoter is a cis-acting transcriptional stabilizer of HNF1A (Nat Cell Biol 2022).Pancreas agenesis mutations disrupt a lead enhancer controlling a developmental enhancer cluster.
(Dev Cell, 2022).Human pancreatic islet 3D chromatin architecture provides insights into the genetics of type 2 diabetes (Nat Genet 2019).Whom would we like to hire?Professional experienceMust HaveYou hold a PhD (or equivalent experience) in statistical genetics, genome or epigenome data analysis, or related fields